logo
‘Cosmic joust': Astronomers catch first sight of two dueling galaxies

‘Cosmic joust': Astronomers catch first sight of two dueling galaxies

CNN23-05-2025
(CNN) — Astronomers have for the first time spotted two galaxies in the throes of a deep-space 'duel.'
Using combined observations from ground-based telescopes over nearly four years, the researchers saw the distant galactic neighbors charging toward each other at more than 1.1 million miles per hour (1.8 million kilometers per hour). One repeatedly wielded its intense beams of radiation at the other, dispersing gas clouds and weakening its opponent's ability to form new stars.
'That's why we call it a 'cosmic joust,'' said Pasquier Noterdaeme, a researcher for the Paris Institute of Astrophysics and the French-Chilean Laboratory for Astronomy in Chile who was part of the team that made the discovery.
What Noterdaeme and his colleagues spied was a distant snapshot of the two galaxies in the process of merging into one large galaxy 11 billion light-years away. The findings, described in a study published Wednesday in the journal Nature, provide a rare look into earlier times in the universe, when star formation and galaxy mergers were more common.
Working with the European Southern Observatory's Very Large Telescope (VLT) and the Atacama Large Millimeter/submillimeter Array (ALMA) in Chile, the researchers found that the 'attacking' galaxy's piercing radiation comes from within its bright core, a quasar, powered by a supermassive black hole.
The intense gravitational influence of a black hole draws matter toward it in such an energetic way that dust and gas heat up to millions of degrees and become luminous, according to NASA. These luminous materials spiral around the black hole before entering, forming what's called an 'accretion disk,' and jets of energetic matter beam out away from the center.
Each blast of the quasar's ultraviolet waves are about a thousand times stronger than the radiation of our Milky Way, causing hydrogen molecules from some of the 'victim' galaxy's star-forming nurseries to split and disperse, according to the study.
Stars form when large clumps of gas and dust reach a critical mass and collapse under their own gravity. However, researchers observed that after being dispersed by the radiation, the clouds were not dense or large enough to create new stars.
As additional material from the victim galaxy is drawn within reach of the supermassive black hole, it fuels the quasar with more energy. Quasars have been known to essentially 'switch off' from time to time, said study coauthor Sergei Balashev, a researcher at the Ioffe Institute in St. Petersburg, Russia, which could give molecular clouds the opportunity to reform.
'It's really the first time that we can see the radiative effect of a quasar on the molecular gas of a nearby galaxy,' Balashev said. Until now, this effect had only been theorized but not confirmed through direct observation.
Scientists initially wanted to observe this particular quasar more closely because of its unique features among thousands of low-resolution spectra, which are like fingerprints for distant celestial objects, offering clues about composition, temperature and activity within them.
'It's really (like) finding a needle in a haystack,' Balashev said. However, the light from quasars is so powerful that it often outshines their own host galaxies, making it difficult to observe other galaxies close by, according to Noterdaeme, the study's co-lead author.
Highly dynamic, luminous quasars are rare, according to NASA. Only about 1,000 of these objects are known to exist in the early days of the universe, Anniek Gloudemans, a postdoctoral research fellow at the National Science Foundation's NOIRLab, previously told CNN via email.
'At first, we just knew there was some molecular gas between the (attacking galaxy's) quasar and us. It's only after, when we started to look with bigger telescopes, that we detected there were actually two galaxies,' Noterdaeme said.
While the dueling pair appears to be overlapping in the low-resolution spectra, the high-resolution imaging capabilities of ALMA revealed the galaxies are actually separated by thousands of light-years. Using the Very Large Telescope, the researchers were able to study the density and distance of the gas affected by the quasar's radiation.
Since the light from these objects came from billions of light-years away in the early universe, it's possible the two galaxies have already merged by now, but there is no way to be sure, Balashev said.
Scientists believe quasars and galaxy mergers used to be far more common earlier in the universe's lifetime, said Dong-Woo Kim, an astrophysicist with the Harvard and Smithsonian Center for Astrophysics who was not involved in the research.
Galaxies merge when they are pulled toward each other by gravity, and the universe used to be more densely packed together. Over time, the universe has expanded, and more galaxies have combined into larger ones, Kim said.
Noterdaeme said that 10 billion years ago was an interesting time in the universe, adding that astronomers call this period when stars formed at a rapid rate the 'noon of the universe.'
Though less frequent, galaxy mergers are still happening all the time, Kim said. Even our own Milky Way is expected to merge with the Andromeda galaxy in a few billion years, but the study team isn't certain yet whether the 'cosmic joust' phenomenon is a common feature when two galaxies collide and form a larger one.
'It's an exciting field to study,' Kim said. 'Research like this can teach us more about the birth of new galaxies and observe how they evolve over time.'
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

New Anti-VEGF Agents Extend Dosing Intervals in Wet AMD
New Anti-VEGF Agents Extend Dosing Intervals in Wet AMD

Medscape

time2 hours ago

  • Medscape

New Anti-VEGF Agents Extend Dosing Intervals in Wet AMD

The advent of second-generation anti-VEGF drugs is transforming the treatment of exudative age-related macular degeneration (AMD) due to their prolonged efficacy, which allows for fewer injections but at the cost of a higher risk for inflammation. A presentation at the 131st Congress of the French Society of Ophthalmology, held in Paris, France, reviewed the impact of these new approaches. The therapeutic management of AMD has undergone significant changes in recent years, the most important of which is undoubtedly the introduction of second-generation anti-VEGF agents (brolucizumab, faricimab, and aflibercept 8 mg), with administration schedules that allow up to 5 months between injections. While these new developments will redefine therapeutic management in AMD, for now, 'it remains difficult to arrive at a simple algorithm,' as management has become so complex, stressed Sarah Mrejen, MD, from the Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts, Paris, during her presentation. Tolerance Concerns Adjustments are particularly expected with the use of new anti-VEGFs, following the emergence of a signal of poorer tolerance in real life with these drugs, particularly brolucizumab. This observation raises questions about the best strategy to follow, particularly after the appearance of intraocular inflammation under second-generation anti-VEGF treatment. AMD is characterized by progressive degeneration of the macula, the central part of the retina. It is the leading cause of vision loss in older adults. In the exudative form of AMD (approximately 10% of cases), abnormal blood vessels develop in the macula, leading to rapid central vision loss. AMD treatment involves intravitreal injections of an anti-VEGF drug under local anesthesia. Ranibizumab and aflibercept 2 mg were the first approved treatments for AMD, with a regimen that includes three consecutive monthly induction injections followed by maintenance doses based on disease activity. These anti-VEGF drugs have allowed better disease control, but 20%-25% of patients still require injections at least every 2 months. To improve the duration of action and avoid patient noncompliance, other anti-VEGF drugs have been developed. Greater 'Drying' Brolucizumab is the first second-generation anti-VEGF to have obtained marketing authorization for AMD in 2020. It is an antibody fragment that targets all isoforms of VEGF-A. The HAWK and HARRIER phase 3 trials demonstrated noninferiority to aflibercept 2 mg. Brolucizumab was administered with monthly injections for the first 3 months of induction. It was then administered every 2-3 months depending on disease activity, while aflibercept was administered every 2 months during the maintenance phase. Results showed that brolucizumab was noninferior in terms of visual acuity after 1 year, and this benefit was maintained up to 2 years. Anatomically, brolucizumab showed superior efficacy, with significantly greater drying of the macula. More than 75% of patients on brolucizumab maintained a 3-month interval between injections. Faricimab is a bispecific antibody targeting both VEGF-A and angiopoietin-2. Its noninferiority to aflibercept 2 mg was demonstrated in the TENAYA and LUCERNE trials. After monthly induction, it was then injected every 2-4 months, depending on disease activity. In both the TENAYA and LUCERNE trials, faricimab maintained visual acuity at 2 years. At that time, 71% of patients in the TENAYA trial and 81% in the LUCERNE trial had an injection interval of 3-4 months compared with the bi-monthly regimen of aflibercept. Finally, aflibercept 8 mg was compared with aflibercept 2 mg in the PULSAR trial. After an induction phase of three monthly injections, patients receiving aflibercept 8 mg were able to switch to injections every 2-4 months depending on disease activity. Again, noninferiority was shown for aflibercept 8 mg. After 2 years, 88% of patients on aflibercept 8 mg maintained an injection interval of at least 3 months. First-Generation Anti-VEGF Drugs These three second-generation drugs are now indicated, alongside first-generation anti-VEGFs, for first-line treatment of exudative AMD, but with different administration regimens. For faricimab, the injection interval cannot exceed 4 months during maintenance compared with 5 months for brolucizumab and aflibercept 8 mg. However, studies have reported differing safety profiles, with brolucizumab being associated with more frequent and severe intraocular inflammation, including retinal vascular occlusions, Mrejen noted. 'These occur later, after 6-8 months of treatment.' In contrast, intraocular inflammations are rare and reversible with both faricimab and aflibercept 8 mg. These typically occur early in treatment, after 2-4 injections. This observation remains to be confirmed in real-world practice with aflibercept 8 mg, 'for which we have less experience.' These findings suggest that first-generation anti-VEGFs still remain a good first-line treatment choice. Ranibizumab and aflibercept 2 mg 'have excellent safety profiles and very good efficacy,' said Mrejen. Cost-Effective Alternatives The advent of biosimilars for first-generation anti-VEGFs, which are more affordable but still underutilized, also supports the preference for these drugs as first-line options. Ranibizumab biosimilars became available in 2023, while aflibercept biosimilars are expected to launch in 2026. However, after the induction phase with first-generation agents, 'if macular fluid control is not optimal, or it is difficult to extend the injection interval beyond 2 months, it is better to switch to second-generation molecules with more potent efficacy,' said Mrejen. Among second-generation anti-VEGFs, brolucizumab occupies a unique place due to its less favorable safety profile. 'It should be reserved for second-line treatment, especially in more severe forms of AMD,' said Mrejen. Faricimab and aflibercept 8 mg, which are better tolerated than brolucizumab, are not recommended as first-line agents 'in the case of prior inflammation.' Ultimately, the use of these new anti-VEGF drugs requires personalized care, with an emphasis on evaluating prior inflammation history before prescribing. Mrejen stressed the importance of having clear communication with patients to explain the early warning signs of intraocular inflammation, such as pain, redness, or blurred vision. In the event of inflammation, patients should be referred for urgent consultation. Precautionary Approach In the case of inflammation under second-generation anti-VEGFs, opinions remain divided on the best course of action to prevent further deterioration into retinal vasculitis. This was revealed during a discussion following the presentation of the session on exudative AMD. Mrejen recommended that once intraocular inflammation resolves, patients should switch to a first-generation molecule. Paris-based ophthalmologist Maté Streho, MD, argued that the therapeutic switch should depend on the severity of the inflammation, especially given patients' reluctance to have more frequent injections. The session moderator, Stéphanie Baillif, MD, PhD, head of the Department of Ophthalmology at the Nice University Hospital, Nice, France, reminded the audience that inflammation under second-generation anti-VEGFs primarily occurs during the induction phase, 'after the first two or three monthly injections.' According to her, patients typically accept switching to a first-generation molecule at this point. The risk also depends on the type of anti-VEGF used. In the case of inflammation under brolucizumab, switching to another second-generation anti-VEGF (faricimab or aflibercept 8 mg) may be considered. However, this is not the case for the reverse scenario. Until more data are available to guide strategies, the precautionary principle should be applied by opting for the better-tolerated molecules, said Baillif.

Harvard physicist says massive interstellar object could be alien probe on 'reconnaissance mission'
Harvard physicist says massive interstellar object could be alien probe on 'reconnaissance mission'

Fox News

time15 hours ago

  • Fox News

Harvard physicist says massive interstellar object could be alien probe on 'reconnaissance mission'

Astronomers recently discovered a rare interstellar object passing through our solar system, and a Harvard physicist is sounding the alarm that its strange characteristics might indicate it's more than just a typical comet. "Maybe the trajectory was designed," Dr. Avi Loeb, science professor at Harvard University, told Fox News Digital. "If it had an objective to sort of to be on a reconnaissance mission, to either send mini probes to those planets or monitor them… It seems quite anomalous." The object — dubbed 3I/ATLAS — was first detected in early July by an Asteroid Terrestrial-impact Last Alert System, or ATLAS, telescope located in Chile. The discovery marked only the third time an interstellar object has been observed entering our solar system, according to NASA. Although NASA has classified the object as a comet, Loeb noted that an image of the cosmic visitor indicated an unexpected glow appearing in front of the object, rather than trailing behind it — something he described as "quite surprising." "Usually with comets you have a tail, a cometary tail, where dust and gas are shining, reflecting sunlight, and that's the signature of a comet," Loeb told Fox News Digital. "Here, you see a glow in front of it, not behind it." Measuring about 20 kilometers across, making it larger than Manhattan, 3I/ATLAS is also unusually bright for its distance. However, according to Loeb, its most unusual characteristic is its trajectory. "If you imagine objects entering the solar system from random directions, just one in 500 of them would be aligned so well with the orbits of the planets," he said. The interstellar object, which comes from the center of the Milky Way galaxy, is also expected to pass near to Mars, Venus and Jupiter — something that is also highly improbable to happen at random, according to Loeb. "It also comes close to each of them, with a probability of one in 20,000," he said. The 3I/ATLAS object will reach its closest point to our sun — about 130 million miles away — on October 30, according to NASA. "If it turns out to be technological, it would obviously have a big impact on the future of humanity," Loeb said. "We have to decide how to respond to that." In January, seven years after SpaceX CEO Elon Musk launched a Tesla Roadster into orbit, astronomers from the Minor Planet Center at the Harvard-Smithsonian Center for Astrophysics in Massachusetts confused it with an asteroid. A spokesperson for NASA did not immediately respond to Fox News Digital's request for comment.

Congressperson Urges NASA to Send Its Jupiter Probe Chasing in Pursuit of the Weird Visitor Coming From Interstellar Space
Congressperson Urges NASA to Send Its Jupiter Probe Chasing in Pursuit of the Weird Visitor Coming From Interstellar Space

Yahoo

time21 hours ago

  • Yahoo

Congressperson Urges NASA to Send Its Jupiter Probe Chasing in Pursuit of the Weird Visitor Coming From Interstellar Space

Earlier this year, astronomers spotted a mysterious interstellar object, dubbed 3I/ATLAS, hurtling through the solar system at a blistering speed. It's only the third confirmed interstellar object to have ventured into our solar system — all over the past few years, owing to more sophisticated space-observing technology — and scientists are eager to have a closer look. Besides detailed observations by the Very Large Telescope in Chile and NASA's Hubble Space Telescope, Harvard astronomer and alien hunter Avi Loeb called on using the space agency's Juno spacecraft to intercept the object's path to get a first-hand look. Loeb, who made headlines last month after suggesting 3I/ATLAS may be an alien probe sent by an intelligent civilization, argued in a blog post that the "close encounter of 3I/ATLAS to Jupiter provides a rare opportunity to shift Juno from its current orbit around Jupiter to intercept the path of 3I/ATLAS at its closest approach to Jupiter." The unique opportunity caught the attention of Representative Anna Paulina Luna (R-FL), who sent a letter to acting NASA administrator Sean Duffy, encouraging the agency to follow Loeb's suggestion. "It is recommended that NASA conduct a study to assess how much fuel is left in Juno's engine, and I support an extension of the Juno mission at least until mid-March 2026 at a cost of about $15M per 6 months from the current expiration date of mid-September 2025," the letter reads. Experts, however, were quick to throw cold water on Loeb's plan, which happens to resemble the plot of Stanley Kubrick's 1968 sci-fi epic "2001: A Space Odyssey." "Juno does not have enough fuel to visit 3I/ATLAS," Penn State astronomy professor Jason Wright tweeted. "Its main engine is also malfunctioning. [Loeb] does (or should) know this because his team was in touch with [Juno principal investigator Scott Bolton]." "An extended mission for Juno would be awesome, but a visit to 3I/ATLAS makes no sense," he added. The spacecraft was launched almost exactly 14 years ago, entering a polar orbit of Jupiter roughly five years later. It was only planned to study the planet until 2018, but it has since doubled the length of its originally planned mission. Not everybody agrees that a mission to visit 3I/ATLAS is out of the question, though. Juno's "current orbit allows it to view Jupiter up close, and its visits to Io [a moon of Jupiter] in 2023 [and] 2024 exposed it to a lot of radiation," University of Kent space professor Mark Burchell told New Scientist. "So it is no surprise it is now showing anomalies in performance that need rebooting." "Could it be re-tasked?" he added. "In theory, if it can be done, and the instruments work, then there is novel data there." Unsurprisingly, intercepting an interstellar visitor that's screaming through outer space at 37 miles per second would be no easy feat even with brand new hardware. Any mission would need a lot of fuel and time to get anywhere near it. According to a yet-to-be-peer-reviewed paper by a team from Michigan State University, a new mission would need to accelerate at 15 miles per second on the day of discovery — which was July 1, so the clock is ticking — to get there in time. However, "spacecraft at Mars could be used to make valuable observations" around late November, when 3I/ATLAS hits its perihelion, or when it makes its closest approach to the Sun. "The perihelion of 3I/ATLAS will not be easily observable from Earth-based observatories, as the object will be on the opposite side of the Sun and at a low solar elongation angle," the paper reads. "However, the object will approach within 0.19 au [or 17.6 million miles] of Mars, and we encourage nearby spacecraft equipped with visible, UV, and IR spectrographs and cameras to attempt to capture data on this object's closest approach." The European Space Agency's Jupiter Icy Moons Explorer (JUICE) may also be able to get a look. The agency's Luca Conversi told New Scientist that "we are aware of this precious opportunity and are currently exploring the technical feasibility." "I'm not sure it is feasible to send it to the comet: unfortunately astro-dynamics is more complicated than what we see in sci-fi movies," he added, "and it is not easy to change the course of spacecraft." Time is quickly running out, and visiting 3I/ATLAS is starting to look like a Herculean task. But to scientists, it's an endeavor worth exploring nonetheless. "The closest approach to Earth will be in December," said coauthor and fourth-year Michigan State undergraduate Atsuhiro Yaginuma in a press release last month. "It would require a lot of fuel and a lot of rapid mobilization from people here on Earth." "But getting close to an interstellar object could be a once-in-a-lifetime opportunity," he added. More on the object: Existing NASA Spacecraft Could Intercept the Weird Interstellar Object Cruising Into Our Star System Solve the daily Crossword

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store